A review of systemic lupus erythematosus and current treatment options

Formulary

Volumn 46, Issue 5, 2011, Pages 178-194

  Bernknopf, Allison ^a   Rowley, Kristina ^a   Bailey, Teresa ^a  

^a FERRIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; SUNSCREEN; TACROLIMUS;

ABDOMINAL DISEASE; AFRICAN AMERICAN; ALOPECIA; ANEMIA; AUTOIMMUNE DISEASE; BLADDER CANCER; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN DISEASE; CAUSAL ATTRIBUTION; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DEHYDRATION; DIARRHEA; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; ETHNICITY; FATIGUE; FEVER; HEREDITY; HERPES SIMPLEX; HISPANIC; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; LYMPHOMA; MACROCYTIC ANEMIA; MALAISE; MYALGIA; NAUSEA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PROTECTIVE CLOTHING; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; STOMATITIS; SUNLIGHT PROTECTION; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VOMITING;

EID: 81155132092     PISSN: 1082801X     EISSN: 19381166     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Miah T, Hoque MA, Mahmood T, Tarafder BK. Clinical profile, management and outcome of lupus. Mymensingh Med J. 2008;17(suppl 2):S6-S11.
2. Jiménez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2003;25:3-11.
3. Bongu A, Chang E, Ramsey-Goldman R. Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol. 2002;16:313-332.
4. Lazaro D. Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. Drugs Aging. 2007; 24: 701-715.
5. Amissah-Arthur MB, Gordon C. GPs have key role in shared care of patients with SLE. Practitioner. 2009;253:19-24.
6. Bae SC, Fraser P, Liang MH. The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis." Arthritis Rheum. 1998;41:2091-2099.
7. Crosslin KL, Wiginton KL. The impact of race and ethnicity on disease severity in systemic lupus erythematosus. Ethn Dis. 2009;19:301-307.
8. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus. 2009;18:935-940.
9. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301:99-105.
10. Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity. 2005;38:507-518.
11. Suh CH, Kim HA. Cytokines and their receptors as biomarkers of systemic lupus erythematosus. Expert Rev Mol Diagn. 2008;8:189-198.
12. Reidenberg MM. Aromatic amines and the pathogenesis of lupus erythematosus. Am J Med. 1983;75:1037-1042.
13. Petri M, Allbritton J. Hair product use in systemic lupus erythematosus: a case-control study. Arthritis Rheum. 1992;35:625-629.
14. Hess EV, Farhey Y. Etiology, environmental relationships, epidemiology, and genetics of systemic lupus erythematosus. Curr Opin Rheumatol. 1995;7:371-375.
15. Zulian F, Pluchinotta FR, Martini G, Da Dalt L, Zacchello G. Severe clinical course of systemic lupus erythematosus in the first year of life. Lupus. 2008;17:780-786.
16. McAlindon T. Update on the epidemiology of systemic lupus erythematosus: new spins on old ideas. Curr Opin Rheumatol. 2000;12:104-112.
17. Sánchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122:430-433.
18. Chen CJ, Lin KH, Lin SC, et al. High prevalence of immunoglobulin A antibody against EpsteinBarr virus capsid antigen in adult patient with lupus with disease fiare: case control studies. J Rheumatol. 2005;32:44-47.
19. Ramos-Casals M, Brito-Zerón P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine. 2007;86:242-251.
20. Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classiflcation of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus. 1999;8:586-595.
21. Weening JJ, D'Agati VD, Schwartz MM, et al, on behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classiflcation of Lupus Nephritis. The classiflcation of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241-250.
22. Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus. 2000;9:166-169.
23. Madhok R, Wu O. Systemic lupus erythematosus. Clin Evid. 2009;7:1123.
24. Gladman D, Urowitz M. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum.1999;42:1785-1796.
25. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195-205.
26. Haq I, Isenberg DA. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice? Best Pract Res Clin Rheumatol. 2002;16:181-194.
27. Petri M. Monitoring systemic lupus erythematosus in standard clinical care. Best Pract Res Clin Rheumatol. 2007;21:687-697.
28. Ghaussy NO, Sibbitt W, Bankhurst AD, Qualls CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol. 2003;30:1215-1221.
29. ® [prescribing information]. Rockville, MD: Human Genome Sciences, Inc., March 2011. Available at: http://www.hgsi.com/images/Benlysta/pdf/benlysta_pi.pdf. Accessed March 29, 2011.
30. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118:1894-1909.
31. Alarcon GS, McGwin G, Bertoli AM, et al, for the LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168-1172.
32. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effects of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577-583.
33. Shapiro T, Goldberg D. Chemotherapy of protozoal infections. In: Brunton L, Lazo J, Parker K, eds. Goodman & Gillman's The Pharmacological Basis of Therapeutics. 11th edition. New York: McGraw Hill, 2006:1032-1041.
34. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF, for the American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2002;109:1377-1382.
35. Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus. 2007;16:387-393.
36. Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum. 2006;36:71-81.
37. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis. 1997;29:193-199.
38. Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. Lupus. 2007;16:212-216.
39. Kuiper-Geertsma DG, Derksen RHWM. Newer drugs for the treatment of lupus nephritis. Drugs. 2003;63:167-180.
40. Navaneethan SD, Viswanathan G, Strippoli GFM. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence. Drugs. 2008;68:2095-2104.
41. Bertsias G, Gordon C, Boumpas DT. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future-the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus. 2008;17:437-442.
42. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008:58:2453-2459.
43. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009:61:1168-1178.
44. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009:61:1143-1151.
45. Navarra SV, Guzmán RM, Gallagher AE, et al; BLISS-52 Study Group. Efflcacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2001;377:721-731.
46. Human genome sciences and GlaxoSmithKline announce full presentation at EULAR of BLISS-76 phase 3 study results for Benlysta in systemic lupus erythematosus. 17 June 2010. Available at: http://www.hgsi.com/latest/human-genomesciences-and-glaxosmithkline-announce-full-presentation-at-eular-of-bliss-76-phase-3-study-results-for-benlysta-in-systemic-lupus-erythema-4.html. Accessed March 29, 2011.
47. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment for lupus nephritis. Cochrane Database Syst Rev. 2004:CD002922.
48. Rheumatrex [prescribing information]. Fort Lee, NJ: DAVA Pharmaceuticals, July 2009. Available at: http://www.rheumatrex.info/pdf/RheumatrexPackageInsert.pdf. Accessed July 20, 2010.
49. CellCept [prescribing information]. South San Francisco, CA: Genentech, February 2010. Available at: http://www.gene.com/gene/products/information/cellcept/pdf/pi.pdf. Accessed July 20, 2010.
50. Imuran [prescribing information]. San Diego, CA: Prometheus Laboratories, April 2009. Available at: http://www.prometheuslabs.com/products_therapeutics_imuran.asp. Accessed July 20, 2010.
51. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2004;43:197-208.
52. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22:1933-1942.
53. Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efflcacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and metaanalysis. Medicine. 2010;89:227-235.
54. Mak A, Cheak AAC, Tan JYS, Su HC, Ho RCM, Lau CS. Mycophenolate mofetil is as efflcacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology. 2009;48:944-952.
55. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19:703-710.
56. Houssiau FA, Cruz DD, Sangle S, et al; the MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for longterm immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083-2089.
57. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for cutaneous lupus erythematosus: American Academy of Dermatology. J Am Acad Dermatol. 1996;34(5 Pt 1):830-836.
58. Callen JP. Update on the management of cutaneous lupus erythematosus. Br J Dermatol. 2004;151:731-736.
59. Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol. 2008;64:337-341.
60. Hermosillo-Romo D, Brey RL. Neuropsychiatric involvement in systemic lupus erythematosus. Curr Rheumatol Rep. 2002;4:337-344.
61. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767-776.
62. Trevisani VFM, Castro AA, Ferreira Neves Neto JJFNN, Atallah AN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2006:CD002265.
63. Zhang FS, Nie YK, Jin XM, Yu HM, Li YN, Sun Y. The efflcacy and safety of lefiunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int. 2009;29:1331-1335.
64. Tam LS, Li EK, Wong CK, Lam CWK, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of lefiunomide in systemic lupus erythematosus. Lupus. 2004;13:601-604.
65. Ramos-Casals M, Diaz-Lagares C, SotoCardenas MJ, et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol. 2011;40:159-169.